Product Description |
Recombinant Human CD164 Protein is expressed from HEK293 with hFc tag at the C-Terminus.It contains Asp24-Asp162. |
Product Background |
CD164 was found to play a role in many malignant diseases. CD164 was associated with clinical and pathological features of patients. High level of CD164 was related to the distant metastasis and vascular invasion of bladder cancer patients.CD164 was associated with the poor clinical outcomes of BC patients. Silencing of CD164 could inhibit the progression of tumors in vivo and in vitro, which may become an effective target in the treatment of bladder cancer. |
Product Category |
Recombinant Protein |
Target |
CD164 |
Synonyms |
MUC-24; Endolyn; MGC-24; Cd164; CD164; MGC-24v; sialomucin |
Accession |
|
Species |
Human |
Biotinylated |
no |
Amino Acid Range |
Asp24-Asp162 |
Molecular Weight |
The protein has a predicted MW of 41.2 kDa. Due to glycosylation, the protein migrates to 110-115 kDa based on Bis-Tris PAGE result. |
Product Tag |
C-hFc |
Express System |
HEK293 |
Purity |
> 95% as determined by Bis-Tris PAGE;> 95% as determined by HPLC |
Endotoxin |
Less than 1EU per ug by the LAL method. |
Form |
Lyophilized |
Shipping |
Shipped at ambient temperature. |
Formulation |
Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 ug/ml is recommended. Dissolve the lyophilized protein in distilled water. |
Stability And Storage |
Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
|
|
Human CD164 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. |
|
|
The purity of Human CD164 is greater than 95% as determined by SEC-HPLC. |
Related Products
Have more questions?
Check out our Frequently Asked Questions page for more details about product specifications, ordering, and shipments.
Contact Us
Recently viewed
